2024
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
Nassar A, Matteson K, Ardeshir F, Gray J, Baena Espinar J, Kwiatkowski D, Aboubakar Nana F, Grohe C, Citarella F, Pancirer D, Cheung J, Watson A, Sridhar A, Crowley F, Kaldas D, Kim C, Sankar K, Awosika N, Naqash A, Chiang A. Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis. Journal Of Clinical Oncology 2024, 42: 8106-8106. DOI: 10.1200/jco.2024.42.16_suppl.8106.Peer-Reviewed Original ResearchLarge cell neuroendocrine carcinomaProgression-free survivalTreatment-related adverse eventsPD-L1 statusOverall survivalPD-L1Systemic therapyRetrospective analysisGrades treatment-related adverse eventsTreatment approachesCell neuroendocrine carcinomaMedian follow-upMulticenter retrospective analysisTreated with chemotherapySystemic treatment approachesChemo-regimenPlatinum-etoposideNeuroendocrine carcinomaOS outcomesLine treatmentToxicity profileClinical outcomesAdverse eventsImmunotherapyIO group
2023
Using real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar.
Li Y, Yang S, Chiang A, Gross C, Wang S. Using real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar. JCO Oncology Practice 2023, 19: 539-539. DOI: 10.1200/op.2023.19.11_suppl.539.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerPD-L1 1First-line therapyCell lung cancerTreatment patternsECOG 2PD-L1Clinical equipoiseLung cancerHHI scoresEastern Cooperative Oncology Group performance scoreFirst-line treatment regimensReal-world practice patternsALK/EGFRActionable gene alterationsStandard of careConfidence intervalsGroup performance scoreComparative effectiveness researchECOG statusOverall cohortPerformance statusECOG scoreTreatment regimens